The synergistic effect of Ivabradine and Olaparib on triple negative breast cancer
Grant Data
Project Title
The synergistic effect of Ivabradine and Olaparib on triple negative breast cancer
Principal Investigator
Professor Khoo, Ui Soon
(Principal Investigator (PI))
Co-Investigator(s)
Dr Tsoi Ho
(Co-Investigator)
Duration
24
Start Date
2020-07-01
Amount
1492110
Conference Title
The synergistic effect of Ivabradine and Olaparib on triple negative breast cancer
Presentation Title
Keywords
breast cancer, combined therapy, Ivabradine, Olaparib, triple negative breast cancer
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
07182026
Grant Type
Health and Medical Research Fund - Full Grant
Funding Year
2019
Status
On-going
Objectives
Triple-negative breast cancer (TNBC) lacks targetable protein for treatment. We previously showed Ivabradine can effectively suppress TNBC growth. The PARP inhibitor Olaparib, interferes with DNA-repair to trigger cancer cell-death in germline-BRCA1/2 mutated breast cancers. Our preliminary data showed that combination of both drugs demonstrated synergetic effect in suppressing TNBC growth. We aim to elucidate the mechanism behind the combined therapy and confirm our preliminary findings using in vivo models.